T1	Participants 478 648	small-cell lung cancer (SCLC) patients who responded to six courses of induction chemotherapy with ifosfamide, etoposide, and an anthracycline (doxorubicin or epirubicin)
T2	Participants 664 813	235 eligible patients initially registered, 91 were randomized to receive maintenance therapy, including seven patients who were no longer responding
T3	Participants 821 934	84 randomized responders, progression-free survival was significantly improved (P = .003) by maintenance therapy,
T4	Participants 1469 1539	maintenance chemotherapy in responding patients is beneficial in SCLC.
